TOP STORIES

• REGULATORY Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
  September 25, 2023

• ACADEMIA Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
  September 25, 2023

• BUSINESS LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
  September 22, 2023

• REGULATORY Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
  September 22, 2023

• BUSINESS Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
  September 21, 2023

• REGULATORY Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
  September 21, 2023

• REGULATORY MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
  September 20, 2023

• REGULATORY Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
  September 20, 2023

• ORGANIZATION JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
  September 19, 2023

• REGULATORY Japan to Require Out-of-Pocket Cost for COVID Drugs from October
  September 19, 2023

• REGULATORY New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
  September 15, 2023

• REGULATORY Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
  September 14, 2023

• REGULATORY Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
  September 14, 2023

• REGULATORY Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
  September 14, 2023

• REGULATORY Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
  September 13, 2023

• REGULATORY Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
  September 12, 2023

• REGULATORY New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
  September 12, 2023

• BUSINESS Sumitomo to Ramp Up Regenerative, Cell Therapy Biz to Counter Latuda Patent Cliff
  September 11, 2023

• BUSINESS After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
  September 8, 2023

• BUSINESS Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
  September 8, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• …
• Next ›
• 最終 »